ADT Does Not Raise Risk of Heart Attacks In Men With No History Of Heart Disease
Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint
MDV3100 Improves Survival, Reduces Death Risk by 37%
Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication
Elevated Baseline Glucose Levels Associated With Higher Cancer Risk
Oncotype DX Cancer Test Can Predict Recurrence
Signet Cell A Rising Trend In Patients Under Age 40
FIT More Effective Than gFOBT In All Colonoscopy Capacities
Tumor Treating Fields Therapy Increased Three-Year Survival
Only 20 Percent Of At-Risk Patients Are Screened For HBV Before Therapy
New Algorithm Completes Scan Three Times Faster Than Before
Survivorship Studies Unfocused As Total Research Increases
Trials Approved by NCI CTEP Last Month
Agency Approves HPV Test That Detects 14 High-Risk Strains
Alimta Granted Approval As NSCLC Continuation Therapy
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - Alec Kimmelman announced as next CEO and Dean of NYU Langone Health
